Elicio Therapeutics, Inc. presented updated preliminary results from the ongoing AMPLIFY-7P Phase 1 clinical trial of ELI-002 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting on November 7, 2024. The data highlighted durable and dose-dependent T cell responses targeting KRAS mutations, along with induced responses to patient-specific neoantigens. These findings suggest a broad and potent immune activation by the ELI-002 vaccine.
A significant observation from the presentation was the correlation between disease-free survival (DFS) and T cell response in patients. This indicates that the immune responses generated by ELI-002 may translate into clinical benefit for patients with mKRAS-driven solid tumors.
The Phase 1 study also confirmed a favorable safety and tolerability profile for ELI-002. Enrollment for the randomized Phase 2 portion of AMPLIFY-7P is expected to be completed in the fourth quarter of 2024, with an interim DFS analysis anticipated in the first half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.